Peri-implant treatment reduces the salivary levels of Colony stimulator factor-1 and S100A8/A9
- PDF / 1,268,868 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 58 Downloads / 134 Views
ORIGINAL ARTICLE
Peri‑implant treatment reduces the salivary levels of Colony stimulator factor‑1 and S100A8/A9 João Martins de Mello‑Neto1 · Mayla Kezy Silva Teixeira2 · Glaucia Schuindt Teixeira2 · Eduardo José Veras Lourenço2 · Daniel Moraes Telles2 · Ronaldo Lira‑Junior3 · Deepak Ipe1 · Raj G. Nair4,5 · Elisabeth Almer Boström3 · Carlos Marcelo Figueredo1 Received: 14 September 2020 / Accepted: 27 October 2020 © The Society of The Nippon Dental University 2020
Abstract This study evaluated the impact of peri-implant treatment in the salivary levels of Colony stimulator factor -1 (CSF-1), S100A8/A9 and S100A12 in patients having mucositis or peri-implantitis. As a secondary aim, we analysed the correlation between the salivary and peri-implant crevicular fluid (PICF) levels. Forty-seven patient, 27 having mucositis (mean age 63.11 ± 7.78) and 20 having peri-implantitis (61.25 ± 7.01) participated in the study. Clinical parameters, probing pocket depth, clinical attachment level, % of plaque and bleeding on probing were evaluated. Unstimulated whole saliva was collected from all patients, while PICF was collected only from a patient’s subgroup (n = 20). Samples were collected before and 3 months after peri-implant treatment. Enzyme-linked immunosorbent assays determined levels of CSF-1, S100A8/ A9 and S100A12. Clinical parameters improved and salivary levels of CSF-1 and S100A8/A9, but not S100A12, reduced significantly after treatment in both groups. No significant correlation was found in the salivary and PICF levels of the same molecule. In conclusion, the treatment of peri-implant disease significantly improved the clinical parameters and reduced the salivary levels of CSF-1 and S100A8/A9. The salivary expressions of CSF-1, S100A8/A9 and S100A12 did not correlate with their own expression in PICF. Keywords CSF-1 · Calprotectin · S100A12 protein · Peri-implantitis · Saliva
Introduction Peri-implant diseases are one of the primary concerns in contemporary dentistry, presenting a prevalence of 46.8 and 19.8% of the individuals with implants developing mucositis * Carlos Marcelo Figueredo [email protected] 1
School of Dentistry and Oral Health and Menzies Health Institute Queensland, Griffith University Queensland, Gold Coast campus Parklands Drive, Southport, QLD 4222, Australia
2
Department of Prosthodontics, Faculty of Odontology, Rio de Janeiro State University, Rio de Janeiro, Brazil
3
Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
4
Oral Medicine and Oral Oncology, Griffith and Menzies Health Institute Queensland, Southport, QLD, Australia
5
Haematology and Oncology, Gold Coast Hospital, Queensland Health, Brisbane, Australia
and peri-implantitis, respectively [1, 2]. While peri‐implant mucositis is defined as a reversible inflammatory reaction in the soft tissues surrounding dental implants, peri-implantitis is characterised by bone loss associated with an inflammatory reaction around an implant in function, which may lead to implant loss [3
Data Loading...
